Home > Gastroenterology > Higher adalimumab dosing regimens may have benefit in ulcerative colitis

Higher adalimumab dosing regimens may have benefit in ulcerative colitis


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
Gastroenterology
Reuters Health - 10/03/2022 - A higher-than-standard maintenance (but not induction) dosing regimen of adalimumab may be beneficial for some patients with moderate to severe ulcerative colitis (UC), according to results of the SERENE UC study.  The study confirms that currently approved doses of adalimumab are effective and well tolerated in inducing and maintaining clinical remission in patients with moderately to severely active UC who fail to respond to conventional therapies, researchers report in Gastroenterology.  The findings also show that weekly adalimumab maintenance dosing "may be appropriate for some patients (eg, those with extensive colitis or low...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on